| PCSK9抑制剂依洛尤单抗在降低心血管事件风险中的研究进展 |
| |
| 引用本文： | 陈文文,李振山,刘妍妍,耿涛,刘燕琳,党和勤,景彩.PCSK9抑制剂依洛尤单抗在降低心血管事件风险中的研究进展[J].中国医院药学杂志,2020,40(3):344-348. |
| |
| 作者姓名： | 陈文文 李振山 刘妍妍 耿涛 刘燕琳 党和勤 景彩 |
| |
| 作者单位： | 1. 山东第一医科大学第二附属医院药剂科, 山东 泰安 271000;2. 滕州市中心人民医院药剂科, 山东 滕州 277500;3. 山东第一医科大学第二附属医院心血管内科, 山东 泰安 271000 |
| |
| 基金项目： | 山东第一医科大学潜力提升计划（编号：2019QL017）；山东省医药卫生科技发展计划（编号：2018WS120）；泰山医学院附属医院青年基金（编号：2014QN05） |
| |
| 摘 要： | 2015年，前蛋白转化酶枯草杆菌蛋白酶/kexin 9（proprotein convertase subtilisin kexin 9，PCSK9）抑制剂依洛尤单抗被美国食品药品监督管理局（the Food and Drug Administration，FDA）批准上市，为高脂血症及心血管高危患者的治疗带来了新的希望。本文综述了依洛尤单抗的药学性质及相关临床试验结果，并介绍其在真实世界中的应用效果，以期为临床药物治疗提供参考。
|
| 关 键 词： | 前蛋白转化酶枯草杆菌蛋白酶/kexin9抑制剂 依洛尤单抗 低密度脂蛋白胆固醇 心血管事件 |
| 收稿时间： | 2019-06-27 |
Research progressof evolocumab in reducing risk of cardiovascular events |
| |
| CHEN Wen-wen,LI Zhen-shan,LIU Yan-yan,GENG Tao,LIU Yan-lin,DANG He-qin,JING Cai.Research progressof evolocumab in reducing risk of cardiovascular events[J].Chinese Journal of Hospital Pharmacy,2020,40(3):344-348. |
| |
| Authors: | CHEN Wen-wen LI Zhen-shan LIU Yan-yan GENG Tao LIU Yan-lin DANG He-qin JING Cai |
| |
| Institution: | 1. Department of Pharmacy, the Second Affiliated Hospital of Shandong First Medical University, Shandong Tai'an 271000, China;2. Department of Pharmacy, Tengzhou Central People's Hospital, Shandong Tengzhou 277500, China;3. Department of Cardiology, the Second Affiliated Hospital of Shandong First Medical University, Shandong Tai'an 271000, China |
| |
| Abstract: | In 2015, evolocumab was approved by the Food and Drug Administration(FDA) as first proprotein convertase subtilisin kexin 9(PCSK9) inhibitor, which brought another therapeutic option for patients with hyperlipidemia and high cardiovascular events risk. This article reviewed the pharmaceutical properties of evolocumab, as well as the data of clinical trial. Meanwhile, its application in the real world was also introduced in order to provide reference for clinical therapy. |
| |
| Keywords: | proprotein convertase subtilisin kexin 9 inhibitor evolocumab low-density lipoprotein cholesterol cardiovascular events |
|
| 点击此处可从《中国医院药学杂志》浏览原始摘要信息 |
| 点击此处可从《中国医院药学杂志》下载免费的PDF全文 |
